Biover­a­tiv inks $100M gene ther­a­py deal with Ox­ford Bio­Med­ica

British gene ther­a­py com­pa­ny Ox­ford Bio­Med­ica has inked a deal worth up to $100 mil­lion to sup­ply ma­te­ri­als to Biover­a­tiv, the gene ther­a­py mak­er who just got snatched by Sanofi for $11.6 bil­lion.

Ox­ford Bio­Med­ica on­ly got $5 mil­lion up front, but could get mile­stone pay­ments of $100 mil­lion down the road, along with roy­al­ties on sales of the he­mo­phil­ia treat­ments Biover­a­tiv is de­vel­op­ing.

Ox­ford Bio­Med­ica is not new to the gene ther­a­py game — the pub­lic com­pa­ny was list­ed in Lon­don in 1996. But thanks to Spark Ther­a­peu­tics, which got the FDA OK to treat blind­ness with gene ther­a­py drug Lux­tur­na late last year, the en­tire field is now com­ing of age. And now Ox­ford Bio­Med­ica is cash­ing in.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.